Illumina to Cut $100 Million in Costs, Lowers Guidance Amid China Sales Ban

Published: Mar. 11, 2025 10:39 p.m. GMT+8

00:00

00:00/00:00

Listen to this article 1x

Illumina is a world leader in the manufacture and sale of genetic-sequencing machines. Photo: Bloomberg

Subscribe to a bundle to unlock all coverage by Caixin Global and the WSJ.

By Jared S. Hopkins

(The Wall Street Journal) — Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines.

San Diego-based Illumina is lowering its 2025 guidance to $4.50 adjusted earnings per share, at the low end of the range of $4.50 to $4.65 a share given last month, Chief Financial Officer Ankur Dhingra told The Wall Street Journal on Monday.